Comparing the conformational behavior of a series of diastereomeric cyclic urea HIV-1 inhibitors using the Low Mode:Monte Carlo conformational search method

Journal of Medicinal Chemistry

Volumn 47, Issue 20, 2004, Pages 4838-4850

  Parish, Carol A ^a   Yarger, Matthew ^a   Sinclair, Kent ^a   Dure, Myrianne ^a   Goldberg, Alla ^a  

^a HOBART AND WILLIAM SMITH COLLEGES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR; UREA DERIVATIVE; WATER;

ARTICLE; BINDING AFFINITY; CALCULATION; CHEMICAL STRUCTURE; CONFORMATION; CRYSTAL STRUCTURE; DIASTEREOISOMER; ENERGY; FORCE; MOLECULE; MONTE CARLO METHOD; QUANTUM CHEMISTRY; SURFACE PROPERTY; VALIDATION PROCESS;

BINDING SITES; HIV PROTEASE; HIV PROTEASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MONTE CARLO METHOD; PROTEIN CONFORMATION; SOLUTIONS; STEREOISOMERISM; UREA;

EID: 4544226381     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049716l     Document Type: Article

References (95)

1. Hodge, C. N.; Straatsma, T. P.; McCammon, J. A.; Wlodawer, A. Rational Design of HIV Protease Inhibitors. Structural Biology of Viruses; Chiu, W., Burnett, R. M., Garcea, R. L., Eds.; Oxford University Press: New York, 1997; pp 451-473.
2. Appelt, K. Crystal Structures of HIV-1 Protease-Inhibitor Complexes. Perspect. Drug Discovery Des. 1993, 1, 23-48.
3. Wlodawer, A.; Erickson, J. W. Structure-Based Inhibitors of HIV-1Protease. Annu. Rev. Biochem. 1993, 62, 543-585.
4. Brik, A.; Wong, C.-H. HIV-1 Protease: Mechanisms and Drug Discovery. Org. Biomol. Chem. 2003, 1, 5-14.
5. Wlodawer, A. Rational Approach to AIDS Drug Design through Structural Biology. Annu. Rev. Med. 2002, 53, 595-614.
6. Tomasselli, A. G.; Heinrikson, R. L. Targeting the HIV-Protease in AIDS Therapy: A Current Clinical Perspective. Biochim. Biophys. Acta 2000, 1477, 189-214.
7. Eron, J. J. J. HIV-1 Protease Inhibitors. Clin. Infect. Dis. 2000, 30, 160-170.
8. Ala, P. J.; Huston, E. E.; Klabe, R. M.; McCabe, D. D.; Duke, J. L.; Rizzo, C. J. Molecular Basis of HIV-1 Protease Drug Resistance: Structural Analysis of Mutant Protease Complexed with Cyclic Urea Inhibitors. Biochemistry 1997, 36, 1573-1580.
9. Hoegl, L.; Korting, H. C.; Klebe, G. Inhibitors of Aspartic Proteases in Human Diseases: Molecular Modeling Comes of Age. Pharmazie 1999, 54, 319-329.
10. Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 Protease: A Major Success of Structure-Based Drug Design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249-284.
11. Ren, S.; Lien, E. J. Development of HIV Protease Inhibitors: A Survey. Progress in Drug Research; Jucker, E., Ed.; Birkhauser Verlag AG: Basel, 1998; pp 4-28.
12. Flexner, C. HIV-Protease Inhibitors. New Engl. J. Med. 1998, 338, 1281-1292.
13. Moore, J. P.; Stevenson, M. New Targets for Inhibitors of HIV-1 Replication. Nat. Rev. Mol. Cell. Biol. 2000, 1, 40-49.
14. De Clercq, E. New Developments in Anti-HIV Chemotherapy. Curr. Med. Chem. 2001, 8, 1543-1572.
15. De Clercq, E. New Developments in Anti-HIV Chemotherapy. Pure Appl. Chem. 2001, 73, 55-66.
16. Hodge, C. N.; Lam, P. Y. S.; Eyermann, C. J.; Jadhav, P. K.; Ru, Y.; Fernandez, C. H.; De Lucca, G. V.; Chang, C.-H.; Kaltenbach, R. F.; Holler, E. R.; Woerner, F.; Daneker, W. F.; Emmett, G.; Calabrese, J. C.; Aldrich, P. E. Calculated and Experimental Low-Energy Conformations of Cyclic Urea HIV Protease Inhibitors. J. Am. Chem. Soc. 1998, 120, 4570-4581.
17. Eyermann, C. J.; Jadhav, P. K.; Hodge, C. N.; Chang, C.-H.; Rodgers, J. D.; Lam, P. Y. S. The Role of Computer-Aided and Structure-Based Design Techniques in the Discovery and Optimization of Cyclic Urea Inibitors of HIV Protease. Advances in Amino Acid Mimetics and Peptidomimetics; Abell, A. D.; Elsevier Science Ltd.: New York, 1997; pp 1-40.
18. Jadhav, P. K.; ala, P.; Woerner, F. J.; Chang, C.-H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. Cyclic Urea Amides: HIV-1 Protease Inhibitors with Low Nanomolar Potency against Both Wild-Type and Protease Inhibitor Resistant Mutants of HIV. J. Med. Chem. 1997, 40, 181-191.
19. Wilkerson, W. W.; Dax, S.; Cheatham, W. W. Nonsymmetrically Substituted Cyclic Urea HIV Protease Inhibitors. J. Med. Chem. 1997, 40, 4079-4088.
20. Nugiel, D. A.; Jacobs, K.; Worley, T.; Patel, M.; III, R. F. K.; Meyer, D. T. Preparation and Structure-Activity Relationship of Novel P1/P1′-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors. J. Med. Chem. 1996, 39, 2156-2169.
21. Sham, H. L.; Zhao, C.; Stewart, K. D.; Betebenner, D. A.; Lin, S.; Park, C. H. A Novel, Picomolar Inhibitor of Human Immunodeficiency Virus Type 1 Protease. J. Med. Chem. 1996, 39, 382-397.
22. Wilkerson, W. W.; Akamike, E.; Cheatham, W. W.; Hollis, A. Y.; Collins, R. D.; DeLucca, I. HIV Protease Inhibitory Bis-Benzamide Cyclic Ureas: A Quantitative Structure-Activity Relationship Analysis. J. Med. Chem. 1996, 39, 4299-4312.
23. Yamazaki, T.; Nicholson, L. K.; Torchia, D. A.; Wingfield, P.; Stahl, S. J.; Kaufman, J. D. NMR and X-ray Evidence That the HIV Protease Catalytic Aspartyl Groups Are Protonated in the Complex Formed by the Protease and a Non-Peptide Cyclic Urea-Based Inhibitor. J. Am. Chem. Soc. 1994, 116, 10791-10792.
24. Kaltenbach, R. F. I.; Klabe, R. M.; Cordova, B. C.; Seitz, S. P. Increased Antiviral Activity of Cyclic Urea HIV Protease Inhibitors by Modifying the P1/P1′ Substituents. Bioorg. Med. Chem. Lett. 1999, 9, 2259-2262.
25. Kaltenbach, R. F. I.; Nugiel, D. A.; Lam, P. Y. S.; Klabe, R. M.; Seitz, S. P. Stereoisomers of Cyclic Urea HIV-1 Protease Inhibitors: Synthesis and Binding Affinities. J. Med. Chem. 1998, 41, 5113-5117.
26. Rodgers, J. D.; Johnson, B. L.; Wang, H.; Erickson-Viitanen, S.; Klabe, R. M.; Bacheler, L.; Cordova, B. C.; Chang, C.-H. Potent Cyclic Urea Hiv Protease Inhibitors with 3-Aminoindazole P2/P2′ Groups. Bioorg. Med. Chem. Lett. 1998, 8, 715-720.
27. Rodgers, J. D.; Lam, P. Y.; Johnson, B. L.; Wang, H.; Ko, S. S.; Seitz, S. P. Design and Selection of DMP 850 and DMP 851: The Next Generation of Cyclic Urea HIV Protease Inhibitors. Chem. Biol. 1998, 5, 597-608.
28. Patel, M.; Kaltenbach, R. F.; Nugiel, D. A.; McHugh, R. J.; Jadhav, P. K.; Bacheler, L.; Cordova, B. C.; Klabe, R. M.; Erickson-Viitanen, S.; Garber, S.; Reid, C.; Seitz, S. P. The Synthesis of Symmetrical and Unsymmetrical P1/P1′ Cyclic Ureas as HIV Protease Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 1977-1082.
29. Patel, M.; Lee, T. B.; Rayner, M. M.; Cordova, B. C.; Klabe, R. M.; Erickson-Viitanen, S. The Synthesis and Evaluation of Cyclic Ureas as HIV Protease Inhibitors: Modifications of the P1/P1′ Residues. Bioorg. Med. Chem. Lett. 1998, 8, 823-828.
30. Han, Q.; Chang, C.-H.; Li, R.; Ru, Y.; Jadhav, P. K.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors: Design and Synthesis of Orally Bioavailable, Pyrazole P2/P2′ Cyclic Ureas with Improved Potency. J. Med. Chem. 1998, 41, 2019-2028.
31. De Lucca, G. V.; Lam, P. Y. S. De Novo Design, Discovery and Development of Cyclic Urea HIV Protease Inhibitors. Drugs Future 1998, 23, 987-994.
32. De Lucca, G. V.; Kim, U. T.; Liang, J.; Cordova, B. C.; Klabe, R. M.; Garber, S.; Bacheler, L.; Lam, G. N.; Wright, M. R.; Logue, K. A.; Erickson-Viitanen, S.; Ko, S. S.; Trainor, G. L. Nonsymmetric P2/P2′ Cyclic Urea Hiv Protease Inhibitors: Structure-Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues. J. Med. Chem. 1998, 41, 2411-2423.
33. Ala, P. J.; Huston, E. E.; Klabe, R. M.; Jadhav, P. K.; Lam, P. Y. S.; Chang, C.-H. Counteracting HIV-1 Protease Drug Resistance: Structural Analysis of Mutant Proteases Complexed with XV638 and SD146, Cyclic Urea Amides with Broad Specificities. Biochemistry 1998, 37, 15042-15049.
34. Kulten, J.; Bonham, N. M.; Nillroth, U.; Hansson, T.; Zuccarello, G.; Bouzide, A. Cyclic HIV-1 Protease Inhibitors Derived from Mannitol: Synthesis, Inhibitory Potencies, and Computational Predictions of Binding Affinities. J. Med. Chem. 1997, 40, 885-897.
35. Bäckbro, K.; Löwgren, S.; Österlund, K.; atepo, J.; Unge, T. Unexpected Binding Mode of a Cyclic Sulfamide HIV-1 Protease Inhibitor. J. Med. Chem. 1997, 40, 898-902.
36. Lam, P. Y. S.; Ru, Y.; Jadhav, P. K.; Aldrich, P. E.; De Lucca, G. V.; Eyermann, C. J.; Chang, C.-H.; Emmett, G.; Holler, E. R.; Daneker, W. F.; Li, L.; Confalone, P. N.; McHugh, R. J.; Han, Q.; Li, R.; Markwalder, J. A.; Seitz, S. P.; Sharpe, T. R.; Bacheler, L. T.; Rayner, M. M.; Klabe, R. M.; Shum, L.; Winslow, D. L.; Kornhauser, D. M.; Jackson, D. A.; Erickson-Viitanen, S.; Hodge, C. N. Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2′ Structure-Activity Relationshop, and Molecular Recognition of Cyclic Ureas. J. Med. Chem. 1996, 39, 3514-3525.
37. Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C.-H.; Eyermann, C. J.; Garber, S. Improved Cyclic Urea Inhibitors of the HIV-1 Protease: Synthesis, Potency, Resistance Profile, Human Pharmacokinetics and X-ray Crystal Structure of DMP 450. Chem. Biol. 1996, 3, 301-314.
38. Kulten, J.; Andersson, H. O.; Schaal, W.; Danielson, H. U.; Classon, B.; Kvarnström, I. Inhibitors of the C2-Symmetric HIV-1 Protease: Nonsymmetric Binding of a Symmetric Cyclic Sulfamide with Ketoxime Groups in the P2/P2′ Side Chains. J. Med. Chem. 1999, 42, 4054-4061.
39. Ala, P. J.; DeLoskey, R. J.; Huston, E. E.; Jadhav, P. K.; Lam, P. Y. S.; Eyermann, C. J.; Hodge, C. N.; Schadt, M. C.; Lewandowski, F. A.; Weber, P. C.; McCabe, D. D.; Duke, J. L.; Chang, C.-H. Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors. J. Biol. Chem. 1998, 273, 12325-12331.
40. Kaltenbach, R. F.; Patel, M.; Waltermire, R. E.; Harris, G. D.; Stone, B. R. P.; Klabe, R. M.; Garber, S.; Bacheler, L.; Cordova, B. C.; Logue, K. A.; Wright, M. R.; Erickson-Viitanen, S.; Trainor, G. L. Synthesis, Antiviral Activity and Pharmacokinetics of P1/P1′ Substituted 3-Aminoindazole Cyclic Urea HIV Protease Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 605-608.
41. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
42. Leach, A. R. Molecular Modeling Principles and Applications; 2nd ed.; Prentice Hall, Pearson Education: Harlow, England, 2001.
43. Senderowitz, H.; Parish, C.; Still, W. C. Carbohydrates: United Atom AMBER* Parametrization of Pyranoses and Simulations Yielding Anomeric Free Energies. J. Am. Chem. Soc. 1996, 118, 2078-2086.
44. Saunders: M.; Houk, K. N.; Wu, Y.-D.; Still, W. C.; Lipton, M.; Chang, G.; Guida, W. C. Conformations of Cycloheptadecane. A Comparison of Methods for Conformational Searching. J. Am. Chem. Soc. 1990, 112, 1419-1427.
45. Weiner, P. K.; Profeta, S.; Wipff, G.; Havel, T.; Kuntz, I. D.; Langridge, R.; Kollman, P. A. A Distance Geometry Study of Ring Systems. Application to Cyclooctane, 18-Crown-6, Cyclododecane and Androstanedione. Tetrahedron 1983, 38, 1113.
46. Grippen, G. M.; Havel, T. F. Distance Geometry and Molecular Conformation; John Wiley: New York, 1988.
47. Havel, T. F. An Evaluation of Computational Strategies for Use in the Determination of Protein Structure from Distance Constraints Obtained by Nuclear Magnetic Resonance. Prog. Biophys. Mol. Biol. 1991, 56, 43.
48. Peishoff, C. E.; Dixon, J. S. Improvements to the Distance Geometry Algorithm for Conformational Sampling of Cyclic Structures. J. Comput. Chem. 1992, 13, 565.
49. Grippen, G. M. Exploring the Conformation Space of Cycloalkanes by Linearized Embedding. J. Comput. Chem. 1992, 13, 351.
50. Fine, R. M.; Wang, H.; Shenkin, P. S.; Yarmush, D. L.; Levinthal, C. Predicting Antibody Hypervariable Loop Conformations. Minimization and Molecular Dynamics Studies of MCPC603 from Many Randomly Generated Loop Conformations". Proteins: Struct., Funct., Genet. 1986, 1, 342.
51. Shenkin, P. S.; Yarmush, D. L.; Fine, R. M.; Wang, H.; Levinthal, C. Predicting Antibody Hypervariable Loop Conformation. Ensembles of Random Conformations for Ring-Like Structures. Biopolymers 1987, 26, 2053.
52. Chang, G.; Guida, W. C.; Still, W. C. An Internal Coordinate Monte Carlo Method for Searching Conformational Space. J. Am. Chem. Soc. 1989, 111, 4379-4386.
53. Weinberg, N.; Wolfe, S. A Comprehensive Approach to the Conformational Analysis of Cyclic Compounds. J. Am. Chem. Soc. 1994, 116, 9860-9868.
54. Li, Z.; Scheraga, H. A. Monte Carlo-Minimization Approach to the Multiple-Minima Problem in Protein Folding. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 6611-6615.
55. Freyberg, B. v.; Braun, W. Efficient Search for All Low Energy Conformations of Met-Enkephalin by Monte Carlo Methods. J. Comput. Chem. 1991, 12, 1065.
56. Kolossvary, I.; Guida, W. C. Low Mode Search. An Efficient, Automated Computational Method for Conformational Analysis: Application to Cyclic and Acyclic Alkanes and Cyclic Peptides. J. Am. Chem. Soc. 1996, 118, 5011-5019.
57. Kolossvary, I.; Guida, W. C. Low-Mode Confomational Search Elucidated: Application to C39h80 and Flexible Docking of 9-Deazaguanine Inhibitors into PNP. J. Comput. Chem. 1999, 20, 1671-1684.
58. Kolossvary, I.; Keseru, G. Hessian-Free Low-Mode Conformational Search for Large-Scale Protein Loop Optimization: Application to C-Jun N-Terminal Kinase JNK3. J. Comput. Chem. 2001, 22, 21-30.
59. Leach, A. R. A Survey of Methods for Searching the Conformational Space of Small and Medium-Size Molecules. Rev. Comput. Chem.; Boyd, K. B. L. a. D. B.; Wiley-VCH: New York, 1991; pp 1-55.
60. Becker, O. Computational Biochemistry and Biophysics; Marcel Decker AG: New York, 2001; 69-90.
61. Goodman, J. M. Chemical Applications of Molecular Modeling; Royal Society of Chemistry: Cambridge, 1998.
62. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macromodel - an Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467.
63. Parish, C.; Lombardi, R.; Sinclair, K.; Smith, E.; Goldberg, A.; Rappleye, M.; Dure, M. A Comparison of the Low Mode and Monte Carlo Conformational Search Methods. J. Mol. Graph. Mod. 2002, 27, 129-150.
64. Luque, F. J.; Barril, X.; Orozco, M. Fractional Description of Free Energies of Solvation. J. Comput.-Aided Mol. Des. 1999, 13, 139-152.
65. Mardis, K. L.; Luo, R.; Gilson, M. K. Interpreting Trends in the Binding of Cyclic Ureas to HIV-1 Protease. J. Mol. Biol. 2001, 309, 507-517.
66. Trylska, J.; Antosiewicz, J.; Geller, M.; Hodge, C. N.; Klabe, R. M.; Head, M. S.; Gilson, M. K. Thermodynamic Linkage between the Binding of Protons and Inhibitors to HIV-1 Protease. Protein Sci. 1999, 8, 180-195.
67. Schaal, W.; Karlsson, A.; Ahlsen, G.; Lindberg, J.; Andersen, H. O.; Danielson, H. U.; Classon, B.; Unge, T.; Samuelsson, B.; Kulten, J.; Hallberg, A.; Karlen, A. Synthesis and Comparative Molecular Field Analysis (CoMFA) of Symmetric and Nonsymmetric Cyclic Sulfamide HIV-1 Protease Inhibitors. J. Med. Chem. 2001, 44, 155-169.
68. Kotamarthi, B. Computational Design of New Cyclic Urea Inhibitors for Improved Binding of HIV-1 Aspartic Protease. Biochem. Biophys. Res. Commun. 2000, 268, 384-389.
69. Wang, L.; Duan, Y.; Stouten, P. F. W.; De Lucca, G. V.; Klabe, R. M.; Kollman, P. A. Does a Diol Cyclic Urea Inhibitor of HIV-1 Protease Bind Tighter Than Its Corresponding Alcohol Form? A Study by Free Energy Perturbation and Continuum Electrostatics Calculations. J. Comput.-Aided Mol. Des. 2001, 15, 145-156.
70. Sussman, F.; Villaverde, M. C.; Martinez, L. Modified Solvent Accessibility Free Energy Prediction Analysis of Cyclic Urea Inhibitors Binding to the HIV-1 Protease. Protein Eng. 2002, 15, 707-711.
71. Katritzky, A. R.; Oliferenko, A.; Lomaka, A.; Karelson, M. Six-Membered Cyclic Ureas as HIV-1 Protease Inhibitors: A Qsar Study Based on Codessa Pro Approach. Bioorg. Med. Chem. Lett. 2002, 12, 3453-3457.
72. Debnath, A. K. Three-Dimensional Quantitative Structure-Activity Relationship Study on Cyclic Urea Derivatives as HIV-1 Protease Inhibitors: Application of Comparative Molecular Field Analysis. J. Med. Chem. 1999, 42, 249-259.
73. Debnath, A. K. Comparative Molecular Field Analysis (CoMFA) of a Series of Symmetrical Bis-Benzamide Cyclic Urea Derivatives as HIV-1 Protease Inhibitors. J. Chem. Inf. Comput. Sci. 1998, 38, 761-767.
74. Gupta, S. P.; Babu, M. S. Quantitative Structure-Activity Relationship Studies on Cyclic Cyanoguanines Acting as HIV-1 Protease Inhibitors. Bioorg. Med. Chem. Lett. 1999, 7, 2549-2553.
75. Gupta, S. P.; Babu, M. S.; Garg, R.; Sowmya, S. Quantitative Structure-Activity Relationship Studies on Cyclic Urea-Based HIV Protease Inhibitors. J. Enzyme Inhib. 1998, 13, 399-407.
76. 4.0, J., Schrodinger, Inc. Portland, OR 1991-2000. www. schrodinger.com.
77. Still, W. C.; Galynker, I. Chemical Consequences of Conformation in Macrocyclic Compounds. Tetrahedron 1981, 37, 3981-3996.
78. In this method the ring is opened by breaking a bond between two ring atoms while allowing other ring torsions to vary. After a new set of ring torsions is generated, the bond is closed subject to closure constraints. In this study the minimum and maximum allowable closure distances for 1 were 0.5 and 2.0 Å, respectively. Closure distances outside of these ranges were discarded before minimization.
79. Ponder, J. W.; Richards, F. M. An Efficient Newton-Like Method for Molecular Mechanics Energy Minimization of Large Molecules. J. Comput. Chem. 1987, 8, 1016.
80. Shenkin, P. S.; McDonald, D. Q. Cluster Analysis of Molecular Conformations. J. Comput. Chem. 1994, 15, 899-916.
81. Weiner, S. J.; Kollman, P. A.; Case, D.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S.; Weiner, P. K. A New Force Field for Molecular Mechanical Simulation of Nucleic Acids and Proteins. J. Am. Chem. Soc. 1984, 106, 765.
82. Kaminski, G.; Friesner, R. A.; Tirado-Rives, J.; W. L. Jorgensen, Evaluation and Reparametrization of the OPLS-Aa Force Field for Proteins Via Comparison with Accurate Quantum Chemical Calculations on Peptides. J. Phys. Chem 2001, 105, 6474-6487.
83. Jorgensen, W. L.; Tirado-Rives, J. The OPLS Potential Functions for Peptides. Energy Minimizations for Crystals of Cyclic Peptides and Crambin. J. Am. Chem. Soc. 1988, 110, 1657.
84. Hasel, W.; Hendrickson, T. F.; Still, W. C. A Rapid Approximation to the Solvent Accessible Surface Areas of Atoms. Tetrahedron Comput. Methodol. 1988, 1, 103-116.
85. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
86. Qiu, D.; Shenkin, P. S.; Hollinger, F. P.; Still, W. C. The GB/SA Continuum Model for Solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii. J. Phys. Chem. A. 1997, 101, 3005-3014.
87. Weiser, J.; Weiser, A. A.; Shenkin, P. S.; Still, W. C. Neighbor-List Reduction: Optimization for Computation of Molecular van der Waals and Solvent-Accessible Surface Areas. J. Comput. Chem. 1998, 19, 797-808.
88. Weiser, J.; Shenkin, P. S.; Still, W. C. Approximate Atomic Surfaces from Linear Combinations of Pairwise Overlaps (LCPO). J. Comput. Chem. 1999, 20, 217-230.
89. Weiser, J.; Shenkin, P. S.; Still, W. C. Fast, Approximate Algorithm for Detection of Solvent-Inaccessible Atoms. J. Comput. Chem. 1999, 20, 586-596.
90. Rao, S. N.; Kollman, P. Simulations of the B-DNA Molecular Dynamics of (Cgcgaattcgcg(2 and D(Gcgcgcgcgc)2: An Analysis of the Role of Initial Geometry and a Comparison of United and All-Atom Models. Biopolymers 1990, 29, 517-532.
91. Reddy, R. M.; Erion, M. D.; Agarwal, A.; Viswanadhan, V. N.; McDonald, Q. D.; Still, W. C. Solvation Free Energies Calculated Using the GB/SA Model: Sensitivity of Results on Charge Sets, Protocols and Force Fields. J. Comput. Chem. 1998, 19, 769-780.
92. RCSB Protein Databank, www.rcsb.org.
93. Yamazaki, T.; Hinck, A. P.; Wang, Y.-X.; Nicholson, L. K.; Torchia, D. A.; Wingfield, P.; Stahl, S. J.; Kaufman, J. D.; Chang, C.-H.; Domaille, P. J.; Lam, P. Y. S. Three-Dimensional Solution Structure of the HIV-1 Protease Complexed with Dmp323, a Novel Cyclic Urea-Type Inhibitor, Determined by Nuclear Magnetic Resonance Spectroscopy. Protein Sci. 1996, 5, 495-506.
94. The contact criteria is defined as C = (distance between atomic centers)(radius atom 1 + radius atom 2)). Bad contacts were those with a ratio less than 0.89 Å.
95. Parish, C. unpublished results.